<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2410">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05129787</url>
  </required_header>
  <id_info>
    <org_study_id>REK255384</org_study_id>
    <nct_id>NCT05129787</nct_id>
  </id_info>
  <brief_title>Ablation vs Resection of Colorectal Cancer Liver Metastases</brief_title>
  <acronym>NEW-COMET</acronym>
  <official_title>A Randomized Controlled Trial of Needle Ablation With 3D Verification vs Surgical Resection of Colorectal Cancer Liver Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      230 patients with colorectal cancer liver metastases will be randomly assigned to resection&#xD;
      or thermal ablation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale: The use of thermal ablation of liver tumors is rapidly increasing. This is despite&#xD;
      a lack of high-level evidence of the oncologic efficacy of ablation. Ablation is most often&#xD;
      used in cases where resection is not possible, but as the technique has improved it is&#xD;
      increasingly used as a substitute for resection. A majority of studies on ablation are&#xD;
      hampered by selection bias. Selection bias can only be overcome in a randomized controlled&#xD;
      trial.&#xD;
&#xD;
      Primary objective:&#xD;
&#xD;
      To compare rates of local tumor progression within 12 months in patients randomly assigned to&#xD;
      thermal ablation or surgical resection of colorectal liver metastases.&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        -  To establish a pipeline for immediate three-dimensional verification of the ablated zone&#xD;
           following thermal ablation of liver metastases.&#xD;
&#xD;
        -  To compare health related quality of life in patients randomly assigned to thermal&#xD;
           ablation or surgical resection of colorectal liver metastases.&#xD;
&#xD;
        -  To perform a cost-effectiveness analysis (Cost per quality adjusted life year) of&#xD;
           thermal ablation and resection of colorectal liver metastases.&#xD;
&#xD;
        -  To compare disease-free and overall survival in in patients randomly assigned to thermal&#xD;
           ablation or surgical resection of colorectal liver metastases.&#xD;
&#xD;
        -  To evaluate the hemodynamic response to thermal ablation and laparoscopic resection of&#xD;
           liver tumors.&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      A randomized, controlled, multicenter, double-blinded non-inferiority trial.&#xD;
&#xD;
      Study population:&#xD;
&#xD;
      Two groups of 115 patients (230 in total) with colorectal liver metastasis eligible for&#xD;
      radical treatment using EITHER resection OR ablation (not a combination).&#xD;
&#xD;
      Intervention:&#xD;
&#xD;
      Ablation of colorectal liver metastases&#xD;
&#xD;
      Control:&#xD;
&#xD;
      Resection of colorectal liver metastases&#xD;
&#xD;
      Main study parameters/endpoints:&#xD;
&#xD;
      The primary endpoint of the study is local recurrence of cancer at 12 months. Secondary&#xD;
      endpoints include overall survival, disease free survival, health related quality of life,&#xD;
      postoperative pain, complications, hospital stay and cost-effectiveness.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>Masking will be performed by large drapings on wounds and masking of operation notes</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Local tumor progression</measure>
    <time_frame>12 months</time_frame>
    <description>Local tumor progression at site of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>60 months</time_frame>
    <description>Overall survival following treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (secondary analysis)</measure>
    <time_frame>60 months</time_frame>
    <description>A secondary analysis will be performed on a oncologically more homogenous group of patients that fulfil the following requirements: a) no previous surgical procedure on the liver, b) no extrahepatic metastases, and c) that had their primary tumor resected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>60 months</time_frame>
    <description>DFS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complications</measure>
    <time_frame>30 days</time_frame>
    <description>Morbidity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>HRQoL is measured using SF-36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-Effectiveness</measure>
    <time_frame>12 months</time_frame>
    <description>An analysis of cost will be performed to assess cost-effectiveness</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">230</enrollment>
  <condition>Colorectal Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>Surgical resection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Liver resection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Thermal ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Thermal ablation (Microwave or radiofrequency)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgical resection</intervention_name>
    <description>Resection of metastasis</description>
    <arm_group_label>Surgical resection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Thermal ablation</intervention_name>
    <description>Ablation of metastasis</description>
    <arm_group_label>Thermal ablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically verified colorectal cancer&#xD;
&#xD;
          -  Colorectal liver metastases (proven or suspected) eligible for radical treatment using&#xD;
             EITHER resection OR ablation (not a combination), as decided by the liver MDT meeting&#xD;
             at the study center&#xD;
&#xD;
          -  The patient is fit to undergo both resection and ablation of all liver metastases&#xD;
&#xD;
          -  Size of largest lesion up to and including 30 mm&#xD;
&#xD;
          -  In case of solitary metastasis, resection plan includes resection of ≤ 2 anatomical&#xD;
             segments.&#xD;
&#xD;
          -  In case of multiple metastases in one continuous resection, resection plan can include&#xD;
             ≤ 4 anatomical segments (including hemihepatectomy)&#xD;
&#xD;
          -  ≤ 5 tumors to be treated in one procedure&#xD;
&#xD;
          -  Primary tumor either resected (primary first) or with a plan for curative treatment&#xD;
             (liver first).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        • More than 3 lung metastases where 1 is &gt;10mm, or 1 lung metastasis &gt;15 mm (OR:&#xD;
        unresectable lung metastases as decided by the lung MDT meeting)&#xD;
&#xD;
          -  Presence of extrahepatic, extrapulmonary metastases.&#xD;
&#xD;
          -  Surgical indication for removal of enlarged lymph nodes in the hepatic hilum.&#xD;
             (Enlarged lymph nodes without indication of removal are not considered an exclusion&#xD;
             criterium)&#xD;
&#xD;
          -  Tumor closer than 10 mm to right/left main bile duct&#xD;
&#xD;
          -  Suspected tumor infiltration to adjacent organs&#xD;
&#xD;
          -  Progression (as of RECIST [18]) on 2nd line chemotherapy&#xD;
&#xD;
          -  Previous inclusion in this trial&#xD;
&#xD;
          -  Not eligible for workup according to study criteria&#xD;
&#xD;
          -  Contraindication to contrast enhanced CT scan&#xD;
&#xD;
          -  Manifest liver cirrhosis&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  ECOG performance status ≥3&#xD;
&#xD;
          -  Simultaneous resection of primary tumor or any other concomitant surgical procedure&#xD;
&#xD;
          -  Any other reason why, in the investigator's opinion, the patient should not be&#xD;
             included.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bjørn Edwin, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Head of clinical research, The Intervention Centre, Oslo University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Åsmund A Fretland, MD PhD</last_name>
    <phone>004723070100</phone>
    <email>aasmund@fretland.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bjørn Edwin, Professor</last_name>
    <phone>004793008635</phone>
    <email>bjoedw@ous-hf.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oslo University Hospital, Department of Gastrointestinal surgery, The National Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 2, 2021</study_first_submitted>
  <study_first_submitted_qc>November 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Åsmund Avdem Fretland</investigator_full_name>
    <investigator_title>Consultant HPB surgeon, MD PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD maybe shared pending approval from local data protection officer</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>3-5 years</ipd_time_frame>
    <ipd_access_criteria>Upon contact to PI</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

